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Abstract Öz 
Purpose: The neutrophil-lymphocyte ratio (NLR), 
platelet-lymphocyte ratio (PLR) and lymphocytopenia are 
markers of poor prognosis in lung cancer patients. The 
aim of this trial is evaluate the prognostic significance of 
basal NLR, PLR and lymphocytopenia in patients with 
extensive stage (ES) small cell lung cancer(SCLC). 
Materials and Methods: This study was designed as a 
hospital-based retrospective observational case-series 
study. A total of 117 patients with extensive stage small 
cell lung cancer have been treated at four different 
oncology centers in Turkey between 2011 and 2017. 
Laboratory results and demographic data were collected. 
Results: The median follow-up time was 12 months and 
95 (81%) patients died. Progression-free survival (PFS) 
and overall survival (OS) were estimated, respectively, as 8 
and 13 months. 65 (55.6 %) patients had complete 
response at the end of first line platin-etoposide 
combination treatment. The cut-off value for NLR and 
PLR were determined for whole group and patients were 
dichotomized into high (≥3.28) and low (<3.28) NLR 
groups and high (≥139.8) and low (<139.8) PLR groups..  
Median OS was lower in patients who had high neutrophil 
lymphocyte ratio (NLR) (14 versus 12 months 
respectively).  
Conclusion: This study showed that basal NLR may have 
prognostic biological value in patients with ES SCLC 
treated with cisplatin + etoposide. 
Amaç: Nötrofil lenfosit oranı (NLR) akciğer kanseri tanılı 
hastalarda kötü prognostic bir belirteçtir. Bu çalışmanın 
amacı yaygın evre küçük hücreli akciğer kanseri  (KHAK) 
tanısı ile tedavi edilen hastaların NLR’leri ile genel 
sağkalım ve tedavi sonuçları ile ilişkisinin incelenmesidir. 
Gereç ve Yöntem: Bu çalışma, hastane tabanlı 
retrospektif gözlemsel olgu serisi bir çalışma olarak 
tasarlanmıştır.2011 ile 2017 yılları arasında yaygın evre 
KHAK tanısı ile tedavi edilen 117 hasta çalışmaya dahil 
edilmiştir. Hastalar tedavi sonrası tam yanıt alınan ve 
alınamayan hastalar olmak üzere 2 gruba ayrıldılar. NLR 
oranları ve demografik veriler hesaplandı. 
Bulgular: Ortalama izlem süresi 12 aydı ve 95 (%81) hasta 
öldü. Progresyonsuz sağkalım (PFS) ve genel sağkalım 
(OS) sırasıyla 8 ve 13 ay olarak hesaplandı. İlk sırada 
platin-etoposid kombinasyon tedavisinin sonunda 65 (% 
55.6) hasta tam yanıt aldı (grup 1). NLR ve PLR için cut-
off değeri tüm grup için belirlenmiş ve hastalar yüksek (≥ 
3.28) ve düşük (<3.28) NLR gruplarına ve yüksek (≥139.8) 
ve düşük (<139.8) PLR gruplarına dikotomize edilmiştir. 
Medyan OS yüksek nötrofil lenfosit oranı (NLR) olan 
hastalarda daha düşüktü (sırasıyla 14'e karşı 12 ay).  
Sonuç: Bu çalışma bazal NLR'nin cisplatin + etoposide ile 
tedavi edilen ES SCLC'li hastalarda prognostik biyolojik 
değere sahip olabileceğini göstermiştir.. 
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INTRODUCTION 
Small cell lung cancer (SCLC) constitutes 
approximately 15% of all lung cancers and the 
estimated number of cases in SCLC is about 29,000 
in 2016 1,2. SCLC is distinguished from other 
tumors by rapid growth with early development of 
metastases. Most of patients presented at the 
extensive stage and could not be treated with 
curative treatment modalities like 
chemoradiotherapy.  Patients have short symptom 
duration. Prognostic factors include ECOG 
performance status, gender, stage, number and 
location of metastases, SIADH and treatment 
response2. Management of ESCLC is nearly same 
over forty years though despite enormous effort on 
SCLC none of targeted treatment strategies or 
investigational immunotherapeutic agents did not 
result with significant improvement of survival 
parameters. Besides, the factors that can predict 
which patients will receive more response to 
treatment are not sufficient. 
Inflammation is closely associated with 
tumorigenesis. Several laboratory markers associated 
with systemic inflammatory responses, including 
plasma C-reactive protein, albumin, hemoglobin, the 
absolute white blood cell count. White cell count or 
its components, NLR3 and platelet‑lymphocyte 
ratios (PLR)4 have been investigated as prognostic 
and predictive markers in patients with different 
types of cancer5. NLR has been used not only as a 
marker of inflammation but also as a prognostic 
index for malignancies6. NLR was not an 
independent prognostic factor4 and was not 
associated with cancer‑specific survival7. Although 
there are various studies in the literature, the 
prognostic role of basal NLR, PLR and 
lymphocytopenia in ES SCLC is still unclear. The 
aim of the present study was to eveluate the 
prognostic role of basal NLR, PLR and 
lymphocytopenia in ES SCLC treated with cisplatin 
+ etoposide. 
MATERIALS AND METHODS 
We designed this study to evaluate the prognostic 
role of basal NLR, PLR and lymphocytopenia in 
ES-SCLC patients treated with cisplatin-based 
combination regimen. In a 6-year-period (Between 
September 2011-December 2017) among 1500 
newly diagnosed lung cancer patients, 117 patients 
with stage 4 Small Cell Lung Cancer were enrolled 
into the study from different four oncology center 
(Sanliurfa Mehmet Akif Inan Education and 
Research Hospital, Acıbadem Mehmet Ali Aydinlar 
University, Ersin Arslan Training and Research 
Hospital and Baskent University Departments of 
Medical Oncology). Patients were histologically 
diagnosed as SCLC by invasive biopsy from main 
lung tumors or metastatic sites of patients. 
Conventional tomography and PET CT was used 
for staging and treatment response evaluation of the 
patients. Ethical approval was sought and granted by 
the institutional ethics committee in Baskent 
University Hospital, Adana, Turkey. Informed 
consent was obtained from all individual 
participants included in the study.   
The clinical and laboratory information of the 
patients was transferred safely from the electronic 
records to the SPSS form. Demographic and 
clinicopathologic variables of the patients were 
determined by considering the disease characteristics 
and follow-up criteria included in the international 
guidelines. Neutrophil, lymphocyte, platelet and 
other laboratory levels of the patients were 
measured at the time of diagnosis before the 
initiation of systemic chemotherapy. Blood samples 
were drawn as a part of diagnostic evaluation at the 
time of diagnosis and were studied at the same time 
with other parameters of serum biochemistry. 
Venous blood samples were put into anticoagulant-
free test tubes for measurement of blood laboratory 
levels. Neutrophil lymphocyte ratio (NLR) was 
calculated as the ratio of the absolute neutrophil 
count to the absolute lymphocyte count and 
platelet‑lymphocyte ratios (PLR) was calculated as 
the ratio of the absolute thrombocyte count to the 
absolute lymphocyte count. Cut-off values were 
calculated using cox regression analysis for NLR and 
PLR. The effect of NLR and PLR on survival 
parameters were examined.. 
Statistical analysis 
All results were presented as the rate for categorical 
values or mean and median for continuous variables. 
Clinical and statistical significant correlation 
between continuous variables was calculated by 
Spearman’s rank correlation test, rs (spearman’s 
correlation coefficient) and p value (2-tailed) were 
noted.   Overall Survival (OS) was defined by the 
time from the date of death and last control minus 
the first day of the chemotherapy. Survival curves 
were estimated according to the Kaplan-Meier 
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method, and log-rank tests were used for univariate 
statistical comparisons. Adjusted Hazard Ratio (HR) 
and 95% confidence interval (95% CIs) were used 
for estimation. Receiver operating characteristic 
curve analysis was performed to determine the NLR 
cut-off All statistical data were analyzed using the 
SPSS version 17.0, and a p value of <0.05 was 
considered statistically significant. 
RESULTS 
Patients 
Patient characteristics are shown in Table 1. The 
median age of the patients was 61 (range 38-81) 
years and 105 (89.7%) patients were male. All of the 
patients (n:117) were stage 4 and 86 (73,5 %) 
patients had oligometastatic disease. Twenty one 
(17,9 %) patients had cranial metastases and 43 
(368%) patients had liver metastases.  
Table-1. Patient and tumor characteristics 
Variable  
Median age (years) (min-max) 61 (39-83) years old 
Gender n (%) 
         Men 105 (89.7) 
         Women  12 (10.3) 
Oligometastatic disease 86 (73.5) 
Cranium Metastases 21 (17.9) 
Liver Metastases 43 (36.8) 
NLR   
            ≥3.28 56 (47.9) 
            <3.28 61 (52.1) 
PLR  
           ≥139.8 67 (57.3) 
           <139.8 50 (42.7) 
Lymphocytopenia 31 (26.5) 
All patients were treated with the platinum 
etoposide combination regimen and 111 patients 
(94,9 %) received cisplatin in combination. The cut-
off value for NLR and PLR were determined for 
whole group and patients were dichotomized into 
high (≥3.28) and low (<3.28) NLR groups and high 
(≥139.8) and low (<139.8) PLR groups. Besides, the 
patients were divided into 2 groups according to the 
presence of lymphocytopenia. 
Treatment and outcomes 
The median follow-up time was 12 months and 95 
(81%) patients died. Progression-free survival (PFS) 
and overall survival (OS) were estimated, 
respectively, as 8 and 13 months (Figure 1, 2). Sixty 
five (55.6 %) patients had complete response (CR) 
with radiological assesment at the end of first line 
platin-etoposide combination treatment. Forty seven 
(72,3 %) patients had CR at the end of treatment 
and 18 (27,7 %) patients had CR at the first analysis 
(after 3 cycle chemotherapy). 
Table 2.  Relationship between systemic 
inflammatory response markers with survival analysis 
Variables 
(median) 
OS p PFS p 
NLR  a   
  High ((≥3.28) 12 0.013a 8 0.97 
  Low (<3,28) 14  8  
PLR       
  High ((≥139.8) 13 0.66 8 0.47 
  Low (<139,8) 13  8  
Lymphocytopenia     
  Yes 12 0.29 8 0.44 
  No 13  9  
a  Statistically significant; OS: Overall survival, PFS: Progression 
free survival  
Patients in the low NLR group had better overall 
survival than those with high NLR (14 versus 12 
months respectively and p=0.013) (Figure-3). There 
was no statistically significant difference in median 
PFS between patients with high NLR and those 
with low NLR (8 versus 8 months respectively and 
p=0.97). 
 
Figure 1. Kaplan–Meier estimates of overall survival 
(OS) of whole patients in the study 
There was no statistically significant relationship 
between PLR groups (<139.8 and >139.8) and OS 
(13 versus 13 months respectively and p=0.66). 
Similarly, there was no statistically significant 
relationship between PLR groups (<139.8 and 
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>139.8) and PFS (8 versus 8 months respectively 
and p=0.47). There was no statistically significant 
relationship between lymphocytopenia and survival 
times (OS and PFS, p=0.29 and p=0,44 
respectively). The relationship between systemic 
inflammatory response markers (NLR, PLR and 
lymphocytopenia) with survival analysis was shown 
in Table 2.   
There was a statistically significant relationship 
between the presence of brain metastasis and NLR 
(p=0,01). But the presence of cranial metastasis was 
not associated with PFS and OS (p=0,89 and 
p=0,66 respectively). Furthermore there was no 
correlation between disease features, response rates 
and these markers (NLR, PLR and 
lymphocytopenia) (Table-3) 
 
Table-3: Relationship between systemic inflammatory response markers  with disease features and 
treatment outcomes 
Variable 
 
NLR PLR Lymphocytopenia 
High Low P High Low P High Low P 
Oligo metastatic disease        
           Yes 42 44 0.72 52 34 0.24 22 64 0.70 
           No 14 17  15 16  9 22  
Cranium metastasis        
       Yes 15 6 0.01 a 14 7 0.33 7 14 0.43 
      No 41 55  52 43  24 72  
Liver metastasis         
      Yes 18 25 0.32 25 18 0.88 10 33 0.54 
      No 38 36  42 32  21 53  
Complete response         
      Yes 29 36 0.43 39 36 0.50 16 49 0.71 
      No 27 25  28 24  15 37  
a  Statistically significant 
  
Figure 2. Kaplan–Meier estimates of progression-free 
survival (PFS) of whole patients in the study 
Figure-3: Patients in the low NLR group had better 
overall survival than those with high NLR (14 versus 
12 months respectively and p=0,013) 
 
DISCUSSION 
In this study we reviewed the prognostic 
significance of basal NLR, PLR and 
lymphocytopenia in ES SCLC patients. The 
important finding of this study is the basal NLRs 
effect on overall survival. Median OS was lower in 
patients who had high neutrophil lymphocyte ratio 
(NLR). Our findings suggest that NLR was an 
independent prognostic marker for ES SCLC 
patients. But PLR and lymphocytopenia are not 
associated with survival.  
The systemic inflammatory response was shown to 
be associated with a poor prognosis in various solid 
tumours. NLR is known as a biomarker with 
prognostic significance for many types of cancer8. 
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NLR, PLR and lymphocyte are easily measurable 
and repeatable parameters. However according to 
best our knowledge, cancer-induced inflammation 
can elevate the NLR, because both neutrophilia and 
relative lymphocytopenia occur in various tumors9. 
Several studies have suggested that increased 
cytokine levels may be responsible for changes in 
the NLR9-12.. 
There are negative and positive studies of NLR in 
different types of cancer in the literature. M H Kang 
et al investigated prognostic role of the NLR in 
SCLC patients and they showed that the prognostic 
significance of NLR for extensive stage patients13. 
Similarly, Liu et al demonstrated the prognostic 
significance of NLR and PLR with their 
retrospective studies with 139 patients. In this trial, 
83 patients were extensive stage disease14. Käsmann 
et al demonstrated that the prognostic significance 
of NLR in limited stage SCLC patients15.The studies 
for significance of NLR in NSCLC patients are 
more than SCLC patients in the literature. Liu H. at 
al showed that PLR maybe a potentially useful 
biomarker for predicting response to first-line 
treatment and prognosis in NSCLC16. In the 
literature, most of PLR studies have been conducted 
in NSCLC patients. The number of studies on 
systemic inflammation biomarkers related to SCLC 
is limited in the literature. Pretreatment 
lymphocytopenia has been showed to be a poor 
prognostic factor in patients with many type of 
cancer17, 18. 
In our study, we also found that high NLR ratios in 
accordance with the literature were poor prognostic. 
However, unlike the literature, the prognostic value 
of PLR and lymphocytopenia could not be 
demonstrated in our study. Prognostic factors 
include ECOG performance status, gender, stage, 
number and location of metastases, SIADH and 
treatment response for ED SCLC and recent 
findings showed that basal NLR maybe one of 
them. Therefore, the present results, may serve 
beneficial in further stratification of SCLC patients 
into different prognostic groups just by using an 
easy to calculate, reproducible and economically 
cheap routine laboratory-test based scoring system 
in addition to other readily available prognostic 
factors. But before this judgment, additional studies 
investigating basal NLR role with other serum 
inflammation markers such as C- reactive protein, 
IL-6, TNF alfa or tissue inflammation signs such as 
tumor infiltrating lymphocytes should be performed. 
There are several limitations of our study including 
retrospectively desingned and including small size 
patients from limited centers.  
In conclusion, high NLR were related poor 
prognosis on ED SCLC patients and we believe that 
the NLR maybe used to predict the mortality risks 
for newly diagnosed ED SCLC patients. 
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